Welcome to the St.Vincent Medical Group. Our more than 500 medical providers stand ready to help you manage your health and wellness. Providing comprehensive care for all your health needs, our physicians specialize in everything from primary care to cardiovascular care and all other services in-between.
We believe finding a physician should be easy. That's why we have our online physician locator or you can call:
March 8, 2013
LAFAYETTE, IND. – Douglas Wallace MD, FACS, board certified cardiothoracic surgeon, has joined St.Vincent Medical Group in Lafayette, Ind. Dr. Wallace's special medical interests are in adult cardiac and thoracic surgery, pediatric cardiac surgery and vascular surgery.
He earned his bachelor's degree in biochemistry from the University of California, Davis, and received his medical degree from Uniformed Services University of Health Sciences, Bethesda, Maryland. Dr. Wallace completed his residency in thoracic surgery from the University of Maryland and a fellowship in pediatric cardiac surgery at the Children's Hospital, San Diego.
He is a member of the American Board of Surgery, the American Board of Thoracic Surgery, and the Society of Thoracic Surgeons. Dr. Wallace is also a Fellow of the American College of Surgeons.
His office is located at 3900 St. Francis Way, Suite 201, Lafayette, IN, 47905. Please call the office at 765-446-7981 for more information, or visit: www.stvincent/medicalgroup/.
INDIANAPOLIS – St.Vincent Heart Center of Indiana is first in the state to participate in a clinical study for a bioresorbable heart stent. St.Vincent Heart Center of Indiana is participating in the landmark clinical trial to implant Absorb™, an investigational bioresorbable vascular scaffold (BVS), as part of the ABSORB III clinical trial. The trial recently started in the United States is manufactured by the healthcare company Abbott. Absorb is a small mesh tube that is designed to open a blocked heart vessel, restore blood flow to the heart and then dissolve into the blood vessel over time. ABSORB III is the first U.S. clinical trial to evaluate the potential benefits of Absorb in comparison to the medicated metallic heart stent, also called a drug-eluting stent, in patients with coronary artery disease (CAD), a form of heart disease.
CAD is a leading cause of death for men and women in the United States. Patients can experience symptoms such as chest pain and shortness of breath when the heart's demand for blood is more than the heart's ability to supply blood due to blockages in the vessels leading to the heart. These blockages are caused by the buildup of fat and cholesterol inside the vessels.
Since the 1970s, physicians have treated CAD patients with balloon angioplasty, metallic and drug-eluting metallic stents, allowing patients to avoid open heart surgery. Unlike a metallic stent that remains permanently in the body, Absorb is referred to as a scaffold to indicate that it is a temporary structure. The Absorb BVS is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures.
The primary endpoint of the trial is target lesion failure, a combined measure of safety and efficacy, at one year. In addition, a subset of patients within the trial will be evaluated for novel endpoints such as vasomotion, a measure of how much natural motion returns to the vessel as Absorb dissolves into the arterial tissue.
Heart disease is the leading cause of death for both men and women in the United States and around the world. Each year, about 785,000 Americans have their first heart attack. Another 470,000 who have already experienced one or more heart attacks have another. Heart disease accounts for one of every six deaths that take place in the U.S.
Abbott is the first company in the world to test a bioresorbable vascular scaffold in patients in the United States.
February 26, 2013
INDIANAPOLIS – Kay Eigenbrod, MD, board certified obstetrics and gynecology, has joined St.Vincent Medical Group in Indianapolis. Dr. Eigenbrod's special interests include hysterectomy, dilation and curettage (D&C), hysteroscopy for fibroid and polyps; uterine prolapse, pre-cancerous cervical conditions, incontinence and heavy bleeding.
Dr. Eigenbrod graduated summa cum laude from Purdue University for her bachelor's degree. She received her medical degree, cum laude, from the University of Illinois, College of Medicine in Peoria. She completed her obstetric and gynecological residency, with honors, at Indiana University Hospital in Indianapolis.
Prior to joining St.Vincent Medical Group, she was associated with St.Vincent Frankfort Hospital for several years where she served on the Executive Committee, and as chief of Surgery and chief of Obstetrics and Gynecology.
Dr. Eigenbrod is a member of the American Medical Association, the Indiana Medical Association and the American Congress of Obstetrics and Gynecology.
Her office is located at 8330 Naab Road, Suite 135, Indianapolis, IN 46260. Please call the office at 317-415-6300 for more information.
February 19, 2013
INDIANAPOLIS – St.Vincent Medical Group officials have announced that the Lung Care Group has joined St.Vincent Medical Group. The six board-certified critical care, pulmonology and sleep specialists have been providing quality health care in Indiana for more than 25 years.
The board certified pulmonary, critical care medicine and sleep medicine physicians are Jerome D. Barnes, MD; William A. Byron Jr., MD; Thomas M. Holian, MD; Brandon J. Perkins, DO; Mitchell A. Pfeiffer, MD; and K. Praveen Vohra, MD.
The critical care and pulmonary physicians provide sophisticated medical care for seriously ill patients facing life-threatening illness or injury in the St.Vincent intensive care units and Trauma Center.
The sleep medicine specialists provide diagnosis and therapy of sleep disorders such as sleep apnea, narcolepsy, insomnia, restless leg syndrome and more. The physicians are skilled in the analysis and interpretation of comprehensive sleep diagnostic tests and provide sleep consultations as well as post-sleep study follow-up. Sleep studies are offered during the day, night and at home through the St.Vincent accredited sleep centers.
Their office is located at 8330 Naab Road, suite 213, Indianapolis, IN 46260 and can be reached at 317-566-0104.
November 16, 2012
INDIANAPOLIS – St.Vincent is participating in a landmark study to evaluate the clinical evidence for safety and efficacy of ultrasound-accelerated thrombolysis (ultrasound energy used with medicine to treat blood clots) in treating patients with life-threatening pulmonary embolism (PE). The study, known as SEATTLE II, is a clinical trial that evaluates the benefits of this advanced treatment technique, which employs a device utilizing ultrasound technology to enhance the speed and efficiency of clot dissolving drugs.
A PE occurs when a large blood clot, usually from a vein in the upper leg, or pelvis, breaks away and lodges in the lungs. The victim's heart may be suddenly overwhelmed with the task of pushing blood past this obstruction. Symptoms are similar to a heart attack.
In this clinical trial, SEATTLE II, a patient is treated by placing a catheter directly into the clotted vein and delivering a clot busting drug into the clot. By doing this, the physician is able to release a lower dosage of the blood clot busting drug, thus decreasing the risk of extensive bleeding.
About 5 percent of PEs are massive; resulting in rapid heart failure and shock. Without immediate therapy death can occur. The traditional method of treating a PE is that a patient receives a large dose of a clot-dissolving drug called a thrombolytic. The drug is delivered into a vein; however, unintended bleeding, often fatal itself, is a much feared side-effect. Up to 40 percent of PE victims have less critical obstructions, often called sub-massive PE, which are currently treated with anti-coagulant medication. These medications do not remove the blood clot; they simply prevent the clot from growing larger. Recently, studies suggest that failure to remove these sub-massive clots may have long-term adverse events including recurrent PE, chronic pulmonary hypertension, and in some cases death. Up to 21 percent of these patients die within 90 days.
The SEATTLE II clinical trial is looking to more efficiently and safely treat PEs that are both massive and sub-massive.
The U.S. Surgeon General reports up to 600,000 patients are stricken with PE in the U.S. resulting in up to 180,000 deaths annually, more than AIDS, breast cancer and auto accidents combined.
November 7, 2012
INDIANAPOLIS – George G. Sheng, MD, board eligible vascular surgeon, has joined CorVasc, a member of St.Vincent Medical Group in Indianapolis. Dr. Sheng's medical specialty is vascular and endovascular surgery and the treatment of thoracic outlet syndrome.
He earned his bachelor's degree in biology as cum laude from Trinity University in San Antonio, Texas. Dr. Sheng received his medical degree from Vanderbilt University School of Medicine in Nashville, Tenn. and completed his surgical residency at University Hospital in Cincinnati, Ohio, where he was Chief Surgical Resident. Dr. Sheng completed his vascular surgery fellowship at Barnes Jewish Hospital at Washington University in St. Louis.
He is a member of the Midwest Vascular Surgical Society.
Dr. Sheng's office is located at 8433 Harcourt Road, Suite 100, Indianapolis, IN 46260. Please call the office at 317-583-7500 for more information, or visit: stvincent.org/medicalgroup.
August 27, 2012
INDIANAPOLIS, IN – St.Vincent Medical Group officials announced the appointment of Bruce Bethancourt, MD, as the chief medical officer for the multi-specialty physician group of primary care and specialty health providers.
As the chief medical officer, Dr. Bethancourt will serve as executive leader and champion for clinical effectiveness, quality and patient safety. In addition, he will provide medical leadership and accountability in clinical outcomes and performance, patient satisfaction, administrative/fiscal operations and strategic planning.
"Dr. Bethancourt has extensive healthcare leadership with large multi-specialty provider groups, and will assist in the growth and development of St.Vincent Medical Group," said John Stewart, president of St.Vincent Medical Group. "His experience in leading quality, safety and various improvement efforts will be integral as we manage health for populations and deliver increased value to patients and families."
Dr. Bethancourt comes to St.Vincent Medical Group from Banner Medical Group, Arizona, where he served in progressive roles as medical director, regional medical director and founding chief medical officer of the multispecialty physician group of more than 650 physicians, nurse practitioners and physician assistants. As chief medical officer, he had key responsibility for the development, implementation, measurement and improvement of all quality initiatives of Banner Medical Group and the creation of their pioneer accountable care organization (ACO).
In addition to his leadership role at Banner Medical Group, he continued his practice of internal medicine at Banner Gateway Medical Center. Dr. Bethancourt's many community commitments include: past president of the Arizona State Medical Association; Adjuvant Clinical Assistant Professor of Medicine, Midwestern Osteopathic School; and senior clinical lecturer at the University of Arizona. Dr. Bethancourt received his medical degree from the University of Arizona, College of Medicine.
St.Vincent Medical Group is physician led and operated, and includes an array of integration options for providers such as clinical affiliations, joint ventures and employment. The multi-specialty physician group sustains the relationships providers have with patients, and creates a model of healthcare delivery that yields enhanced quality, efficiency, access and cost reductions.
Use the above Find a Physician online search tool to find a doctor in your area.
St.Vincent Medical Group Administration; 10330 N. Meridian St. Indianapolis, INPhone; 317-583-7864